子痫前期相关孕产妇不良结局预测模型的开发与验证:回顾性队列研究
该回顾性队列研究纳入中国三家医院2019年1月至2023年12月诊治的1400例子痫前期单胎孕妇,按7:3随机分为训练集979例和验证集421例,识别孕产妇不良结局的独立危险因素并构建两个列线图模型。模型1预测绝对风险,训练集AUC 0.93、验证集0.92;模型2预测诊断后3、5、7天无事件生存可能性,验证集AUC分别为0.79、0.82、0.88。
要点
- 模型1预测子痫前期孕产妇不良结局的绝对风险,验证集AUC为0.92。
- 模型2预测诊断后3、5、7天无事件生存可能性,验证集AUC分别为0.79、0.82、0.88。
- 视觉障碍、平均动脉压≥120 mmHg、24小时尿蛋白升高等为独立危险因素。
核心结论
- 研究识别了子痫前期孕产妇不良结局的关键临床预测因素,并开发了两个列线图模型用于风险分层;验证后的预测模型为早期识别高危患者提供了可靠工具,有助于及时临床干预以改善孕产妇结局。
研究设计与样本
- 回顾性队列研究,纳入中国三家医院2019年1月至2023年12月诊治的1400例子痫前期单胎孕妇,按7:3随机分为训练集979例和验证集421例,分析诊断时临床特征和实验室参数。
诊断标准与关键数值
- 模型1基于多因素logistic回归预测绝对风险,训练集AUC 0.93(95%CI 0.92-0.95),验证集AUC 0.92(95%CI 0.89-0.95)。模型2基于Cox回归预测诊断后3、5、7天无事件生存可能性,训练集AUC分别为0.81(95%CI 0.75-0.87)、0.86(95%CI 0.82-0.89)、0.89(95%CI 0.87-0.92),验证集AUC分别为0.79(95%CI 0.70-0.88)、0.82(95%CI 0.75-0.89)、0.88(95%CI 0.84-0.92)。
临床应用与阅片要点
- 模型1可用于子痫前期诊断时评估孕产妇不良结局的绝对风险,模型2可估计诊断后3、5、7天无事件生存的可能性,两个模型校准曲线显示预测概率与观察概率高度一致,决策曲线分析证实临床效用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Pre-eclampsia (PE) is a major contributor to maternal morbidity and mortality. This study aimed to identify clinical risk factors for maternal adverse outcome in women with PE, and to assess the time to event using predictive modeling.
METHODS: This retrospective cohort study included women with a singleton pregnancy diagnosed with PE who received antenatal care between January 2019 and December 2023 at one of three hospitals in China. Participants were assigned randomly into a training set and a validation set in a 7:3 ratio. Clinical characteristics and laboratory parameters collected at the time of PE diagnosis were analyzed to identify risk factors for maternal adverse outcome using univariate and multivariate logistic regression. Cox regression analysis was employed to examine factors associated with time to maternal adverse outcome. Two predictive nomogram models were developed: Model 1, which was based on multivariate logistic regression and predicts the absolute risk of maternal adverse outcome; and Model 2, which was derived from Cox regression coefficients and estimates the likelihood of maternal event-free survival at 3, 5 and 7 days after PE diagnosis. Model performance was assessed using the area under the receiver-operating-characteristics curve (AUC), calibration curves and decision-curve analysis.
RESULTS: A total of 1520 women diagnosed with PE were screened, of whom 1400 were included based on predefined inclusion and exclusion criteria; 979 were assigned to the training set and 421 to the validation set. Multivariate logistic regression identified the following variables as significant independent risk factors for maternal adverse outcome: maternal age ≥ 35 years, prepregnancy body mass index (underweight, overweight or obese), irregular antenatal care, earlier gestational age at presentation, visual disturbance, mean arterial pressure ≥ 120 mmHg, elevated 24-h urine protein, elevated soluble fms-like tyrosine kinase-1 to placental growth factor ratio, low hemoglobin, elevated aspartate aminotransferase, total bilirubin > 15.9 μmol/L and serum urea > 7.5 mmol/L. Cox regression confirmed that these factors were associated significantly with time to maternal adverse outcome, with the exception of elevated total bilirubin and serum urea. Model 1 demonstrated excellent predictive performance, with an AUC of 0.93 (95% CI, 0.92-0.95) in the training set and 0.92 (95% CI, 0.89-0.95) in the validation set. Model 2 achieved AUC values of 0.81 (95% CI, 0.75-0.87), 0.86 (95% CI, 0.82-0.89) and 0.89 (95% CI, 0.87-0.92) in the training set and 0.79 (95% CI, 0.70-0.88), 0.82 (95% CI, 0.75-0.89) and 0.88 (95% CI, 0.84-0.92) in the validation set for predicting maternal adverse outcome at 3, 5 and 7 days after PE diagnosis, respectively. For each model, calibration curves showed strong agreement between predicted and observed probabilities, while decision-curve analysis confirmed the clinical utility of both models.
CONCLUSIONS: This study identified key clinical predictors of maternal adverse outcome in women with PE and developed two nomogram models for risk stratification. The validated predictive models offer reliable tools for the early identification of high-risk patients, facilitating timely clinical intervention to improve maternal outcome. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Huang M, Xie W, Kang L, et al. Development and validation of prediction model for pre-eclampsia-related maternal adverse outcome: retrospective cohort study. Ultrasound Obstet Gynecol. 2025. PMID: 40878350. doi:10.1002/uog.70001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。